TTP

In contrast, immunoglobulin is cost effective, readily available at most hospitals, and has a track record of long-term safety. readily available, and has a verified long-term security record, making it a possible treatment option for acquired thrombotic thrombocytopenic purpura. strong class="kwd-title" Keywords: ADAMTS13, ADAMTS13 inhibitor, intravenous immunoglobulin, plasmapheresis, thrombotic thrombocytopenic purpura 1.?Intro Acquired thrombotic thrombocytopenic purpura (TTP) is Macbecin I caused by ADAMTS13 (a disintegrin-like and metalloproteinase with Macbecin I thrombospondin type 1 motif, 13) inhibitor.[1,2] Plasma exchange, used to remove the ADAMTS13 inhibitor and replenish ADAMTS13, is the principal treatment for acquired TTP and offers reportedly reduced mortality from 90% to 10% to 20%. The English Society for Haematology recommendations recommend starting plasma exchange immediately after the analysis of TTP.[3] Plasma exchange, however, is invasive and may have adverse..

Primary location: Burlington United States